Affordable Access

Access to the full text

Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)

Authors
  • Schmidt-Erfurth, Ursula
  • Garcia-Arumi, Jose
  • Bandello, Francesco
  • Berg, Karina
  • Chakravarthy, Usha
  • Gerendas, Bianca S.
  • Jonas, Jost
  • Larsen, Michael
  • Tadayoni, Ramin
  • Loewenstein, Anat
Type
Published Article
Journal
Ophthalmologica
Publisher
S. Karger AG
Publication Date
Apr 20, 2017
Volume
237
Issue
4
Pages
185–222
Identifiers
DOI: 10.1159/000458539
PMID: 28423385
Source
Karger
Keywords
License
Green
External links

Abstract

Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease.

Report this publication

Statistics

Seen <100 times